[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-liver-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-liver-metastases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,76,99,125,148,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100639946","transplantation-vs-resection-after-conversion-therapy-for-initially-unresectable-colorectal-liver-metastases-100639946",false,"NCT07607873","TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases","TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable","TRANSECT","Inclusion Criteria screening phase (before randomization):\n\n* Signed screening phase informed consent.\n* Age \\>18.\n* Performance status score of Eastern Cooperative Oncology Group (PS-ECOG) 0-1\n* Adequate organ functions.\n* Liver-limited Metastatic Disease Confirmed as Unresectable by Colorectal Oncology Multidisciplinary Tumor Board (MTB).\n* Histologically documented adenocarcinoma of the colon or intra-peritoneal rectum\n* Absence of extra-hepatic disease demonstrated by contrast-enhanced CT + MRI and, in clinically indicated (clinical suspicion or elevated biomarkers), FDG-PET.\n* No previous systemic treatment for unresectable disease.\n* No previous systemic treatment for primary tumor resection\n* Recurrence occurring beyond six months after completion of adjuvant treatment.\n* MMR proficient cancer (MSS) regardless of RAS mutational status, BRAF-WT except for BRAF V600E-mut treated and responding to anti-BRAF + cytotoxic therapy.\n\nExclusion criteria:\n\n* Absolute contraindication to liver transplant.\n* Other malignancies in the previous 5 years excluding non melanoma skin-cancers or in situ disease.\n* Hereditary CRC syndromes including FAP and Lynch syndrome.\n* Previous extrahepatic metastatic localization or locoregional tumor recurrence.\n* Extra-peritoneal cancers.\n* BRAFV600E-mut patients non-responder to 1st line anti-BRAF + cytotoxic therapy (Elez et al NEJM 2025, ref. 8)\n\nRandomization inclusion criteria:\n\n* Signed randomization phase informed consent.\n* CEA \\\u003C 80 ng\u002Fml or decrease in CEA level at least 50% from baseline (TRANSMET criteria (5)).\n* Conversion to resectability according to MTB discussion during first 6 months of induction chemotherapy.\n* Sustained objective response defined as stable disease (SD), partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria (19), under chemotherapy, for at least 3 months.\n* Surgical resection of the primary tumor with a high oncological standard, as outlined in The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer (20), ensuring safe margins of resection and adequate TNM staging.\n* Histologically confirmed primary tumor staged as pT4a and\u002For pN2, with achievement of R0 resection. In patients with pT4a and\u002For pN2 disease, only metachronous metastases are eligible. For pT4a tumors, a minimum disease-free interval of 6 months from primary tumor resection is required before randomization.\n* Time from primary resection to liver transplantation or radical local treatment \\>6 months\n* Absence of local recurrence and extra-hepatic disease demonstrated by contrast-enhanced CT + MRI and, in clinically indicated (clinical suspicion or elevated biomarkers), FDG-PET.\n* PS-ECOG 0-1. Adequate organ functions.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","The TRANSECT trial is a prospective randomized study designed to evaluate the role of liver transplantation (LT) versus radical local treatment (hepatic resection and\u002For ablation) in patients with initially unresectable colorectal liver metastases (CRLM) converted to resectability after conversion therapy.\n\nLiver metastases are the leading cause of mortality in colorectal cancer patients. Although hepatic resection combined with chemotherapy remains the standard curative-intent treatment, only a minority of patients are eligible for upfront surgery. Advances in modern conversion chemotherapy have substantially increased the proportion of patients who can subsequently undergo curative local treatment. However, liver resection after intensive chemotherapy is still associated with high rates of intrahepatic recurrence, risk of R1 resections, chemotherapy-induced liver injury, and the need for complex surgical procedures carrying considerable morbidity and mortality. In parallel, recent studies investigating LT for unresectable CRLM, including the TRANSMET trial, demonstrated highly promising oncological outcomes, with 5-year overall survival rates exceeding 50% in selected patients.\n\nBased on these findings, the TRANSECT trial hypothesizes that LT may represent a more effective therapeutic strategy also in patients initially deemed unresectable but subsequently converted to resectability, by completely removing the hepatic metastatic niche.\n\nTRANSECT is a single-center, randomized, open-label, proof-of-concept trial. Patients with liver-only CRLM initially assessed as unresectable by a dedicated multidisciplinary tumor board and subsequently converted to resectability after systemic therapy will be randomized to either LT or hepatic resection and\u002For ablation. The primary endpoint is 3-year intention-to-treat overall survival (OS). Secondary endpoints include perioperative morbidity and mortality, disease-free survival, treatment adherence, quality of life, and exploratory translational analyses including radiomics and circulating tumor DNA assessment.\n\nA total of 70 patients (35 per arm) will be enrolled, with an estimated overall study duration of 5 years. TRANSECT represents the first randomized trial directly comparing LT and liver-directed surgery in patients with initially unresectable CRLM converted to resectability after systemic therapy, with the aim of redefining curative treatment strategies in this selected patient population.",[27],"Colorectal Liver Metastases",[29,27,30,31,32],"Liver Transplantation","Conversion Therapy","Liver Resection","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-05-22",{"date":36,"type":37},"2026-05-26","ACTUAL",{"date":39,"type":21},"2026-06-15",{"date":41,"type":21},"2031-06-15",{"name":43,"class":44},"Niguarda Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100554622","phase-3-adjuvant-folfiri-based-chemotherapy-after-resection-of-clm-responding-to-preoperative-folfiri-100554622","NCT06501482","Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","\"Interest of Postoperative Reintroduction of Chemotherapy in Patients Undergoing Resection of Colorectal Liver Metastases After Good Response to FOLFIRI-based Chemotherapy With or Without Targeted Agent\" (Intergroup FRENCH- PRODIGE)","IRIMAD","Inclusion Criteria:\n\n* Histologically proven resected metachronous CLM with curative intent that could not be treated with perioperative oxaliplatin-based chemotherapy for oncologic or tolerability reasons. For this study, metachronous CLM is defined as liver recurrence occurring more than 12 months after treatment of the primary colorectal cancer.\n* No more than 10 treated CLM at surgery\n* At least 2 cycles and no more than 8 cycles of preoperative FOLFIRI based chemotherapy ± targeted therapy.\n* Preoperative FOLFIRI based chemotherapy ± targeted therapy administered no more than 12 weeks before surgery\n* R0\u002FR1resection ± radiofrequency ablation with curative intent of all liver deposits with no macroscopic residual liver disease\n* Objective response to preoperative therapy defined as complete or partial radiological response and\u002For major or complete pathologic response\n* No extrahepatic or residual liver disease on baseline work-up including thoraco-abdominal CT scan within 6 weeks after surgery. 1 non-specific lung nodule of less than 10 mm in maximum diameter is not considered as extra-hepatic metastases\n* Primary tumor (or liver metastasis) of CRC must be characterized for RAS and BRAF status\n* No contraindication to FOLFIRI based chemotherapy\n* Patients must be 18 years old or older\n* A WHO performance status of 0 or 1\n* Participants must be affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Palliative\u002FR2 resection of CLM\n* 10 lesions or more treated at the time of surgery\n* Patients undergoing only radiofrequency ablation of all liver deposit (this situation precludes the assessment of pathologic response to preoperative chemotherapy)\n* Extra-hepatic or residual metastasis of CRC\n* Absence of objective response to therapy (radiological or pathological response )\n* Inflammatory bowel disease\n* Known UGT1A1\\*28 allele homozygosity\n* complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level ≥ 150 ng\u002Fml\n* Contraindications to investigational medicinal products (irinotecan, 5-FU, folinic acid) and to auxiliary medicinal products (ondansetron, methylprednisolone)\n* Persistent toxicity ≥ grade 1 related to preoperative FOLFIRI based chemotherapy\n* Known pregnancy (pregnancy test for women of childbearing) or breastfeeding women",{"count":54,"type":21},254,[56],"PHASE3","Eligible patients are patients with contraindication to preoperative oxaliplatin based-chemotherapy who underwent resection of no more than 10 colorectal liver metastases after preoperative FOLFIRI based chemotherapy with or without targeted agents. These patients must have objective response to treatment (radiologic or pathologic response). The standard care for these patients is no postoperative treatment although benefit of reintroduction of FOLFIRI chemotherapy in good responders could be expected.\n\nThis study is a National, multicenter, open-label randomized, 2-arm, phase III superiority trial comparing postoperative reintroduction of FOLFIRI based-chemotherapy (experimental arm) vs no treatment (control arm) in patients undergoing resection of colorectal liver metastases after good response to FOLFIRI-based chemotherapy with or without targeted agent.\n\nThe primary endpoint of the study is 3-year disease free survival. Based on published data, 3-year DFS in control group (absence of postoperative treatment is 25%. Expected 3-year DFS in the experimental group is 40%. The study will randomize 254 patients (127 in the chemotherapy group and 127 in the no treatment group) in 30 french academic centers.",[59,27],"Colorectal Cancer",[61,62,63,64],"Resected colorectal liver metastases","Response to preoperative chemotherapy","Postoperative FOLFIRI based chemotherapy","Disease-free survival","RECRUITING","2026-02-02",{"date":68,"type":37},"2026-02-04",{"date":70,"type":37},"2025-06-27",{"date":72,"type":21},"2031-06-27",{"name":74,"class":44},"Assistance Publique - Hôpitaux de Paris",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":75},"100623005","integrated-clinical-molecular-risk-stratification-to-early-recurrence-in-colorectal-liver-metastases-100623005","NCT07391007","Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases","A Multidimensional Early-Recurrence Risk Stratification System and Personalized Treatment for Colorectal Cancer Liver Metastases: A Prospective Clinical Study","Inclusion Criteria:\n\n1. Aged 18 to 75 years, inclusive (male or female).\n2. Pathologically and radiologically confirmed colorectal cancer with liver metastases.\n3. Must have undergone complete (R0) surgical resection of both the primary colorectal tumor and all liver metastases.\n4. Have adequate organ function and no contraindications to potential adjuvant therapies (surgery, chemotherapy, radiotherapy, immunotherapy).\n5. Willing and able to comply with the study protocol and follow-up visits.\n6. Availability of sufficient liver metastasis tumor tissue for gene sequencing.\n7. Provision of a blood sample for circulating tumor DNA (ctDNA) detection within one month after surgery but before starting any adjuvant therapy.\n\nExclusion Criteria:\n\n1. Pregnancy or breast-feeding women\n2. History of other malignancies within 5 years (except cured skin cancer and cervicalcancer in situ)\n3. History of uncontrolled epilepsy, central nervous system disease, or psychiatricdisorders\n4. Clinically serious heart disease, such as symptomatic coronary artery disease, NewYork Heart Association (NYHA) class II or worse congestive heart failure or severearrhythmia requiring pharmacologic intervention, or history of myocardial infarctionwithin the last 12 months\n5. Baseline blood and biochemical indicator do not meet the following criteria:neutrophils \\>=1.5×10\\^9\u002FL, Hb \\>=90g\u002FL, PLT \\>=100×10\\^9\u002FL, ALT\u002FAST\\\u003C=2.5 ULN, Cr \\\u003C= 1ULN\n6. Allergic to any component of the therapy\n7. Severe uncontrolled recurrent infections","75 Years",{"count":85,"type":21},200,"2 Years","OBSERVATIONAL","The goal of this observational study is to develop an integrated clinical-molecular risk stratification to identifypatients who are at high risk of recurrence and who would benefit from adjuvant chemotherapy in patients with recectable colorectal liver metastases. The main question it aims to answer is: can the integration of multi-dimensional data-including ctDNA, driver gene profiles, and clinical factors-accurately identify postoperative patients at high risk of recurrence and guide personalized adjuvant therapy strategies?",[27],"2026-01-29",{"date":92,"type":37},"2026-02-05",{"date":94,"type":21},"2026-01-31",{"date":96,"type":21},"2028-04-30",{"name":98,"class":44},"Fudan University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":75},"100581325","phase-2-ivonescimab-plus-chemotherapy-in-patients-with-initially-unresectable-colorectal-cancer-liver-metastases-100581325","NCT06848842","Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","A Phase II Clinical Study of Ivonescimab Plus CAPOX Regimen in Patients With Initially Unresectable Colorectal Cancer Liver-only Metastases","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically confirmed colorectal adenocarcinoma.\n3. Radiologically confirmed liver-only metastases. Patients with ≤1 cm extrahepatic lesions not confirmed as metastatic are eligible.\n4. No prior systemic therapy or local therapy for metastatic lesions, or completion of neoadjuvant\u002Fadjuvant chemotherapy ≥6 months before diagnosed disease recurrence.\n5. Liver metastases considered unresectable or borderline resectable by multidisciplinary evaluation.\n6. Liver metastases were measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n7. Eastern Cooperative Oncology Group performance status 0-1\n8. Life expectancy ≥12 weeks.\n9. No contraindications to hepatic resection\u002Fablation, and primary tumor resectable or previously resected.\n10. Adequate organ function as determined by normal bone marrow function (hemoglobin ≥80 g\u002FL, absolute neutrophil count ≥1.5×10⁹\u002FL, and platelets ≥100×10⁹\u002FL), renal function (serum creatinine ≤1.5×upper limit of normal \\[ULN\\] and creatinine clearance ≥30 mL\u002Fmin), liver function (serum bilirubin ≤2×ULN and serum transaminases ≤5×ULN).\n\nExclusion Criteria:\n\n1. Definite extrahepatic metastases.\n2. dMMR or MSI-H colorectal cancer.\n3. Intolerance to the study drug during prior neoadjuvant\u002Fadjuvant therapy.\n4. Toxicities from prior therapy have not resolved to ≤ Grade 1 (according to NCI-CTCAE v5.0), except for alopecia (any grade) and peripheral neuropathy (≤ Grade 2).\n5. History of or concurrent other malignancies within the past 5 years, except cured localized tumors.\n6. Surgery performed within 28 days prior to enrollment.\n7. Hypertension with systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg despite antihypertensive treatment.\n8. Major cardiovascular events within 12 months prior to enrollment.\n9. History of severe bleeding tendency or coagulation disorders; tumor encasement of major blood vessels or significant necrosis or cavitation, and the investigator deems participation in the study may pose a bleeding risk.\n10. Active autoimmune disease requiring systemic treatment within the past 2 years.\n11. History of immunodeficiency, positive HIV antibody test, or long-term use of corticosteroids or other immunosuppressants.\n12. Prior history of allogeneic bone marrow or organ transplantation.\n13. Received live vaccines within 30 days prior to the first dose or plans to receive live vaccines during the study period.\n14. Allergy to any component of the study drugs; history of severe hypersensitivity reactions to other monoclonal antibodies.\n15. Women who are pregnant or breastfeeding.\n16. Severe comorbidities or any other condition that precludes safe administration of the study treatment, including but not limited to symptomatic congestive heart failure (Class II or higher per NYHA classification), unstable angina, acute myocardial ischemia, poorly controlled arrhythmias, decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or psychiatric\u002Fsocial conditions that may limit compliance with study requirements or impair the subject's ability to provide written informed consent.\n17. Any other condition deemed by the investigator as unsuitable for participation in this study.",{"count":107,"type":21},40,[109],"PHASE2","The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aims to answer are:\n\nDoes ivonescimab plus chemotherapy raise the objective response rate? What medical problems do participants have when receiving ivonescimab plus chemotherapy?\n\nParticipants will:\n\nReceive ivonescimab and chemotherapy every 3 weeks, no more than 8 cycles. Visit the clinic once every 2 cycles (6 weeks) for checkups and tests. Receive curative surgery, maintenance therapy, or discontinue study treatment according to the expert team's evaluation.",[27],[27,113,114,115],"initially unresectable","ivonescimab","objective response rate","2025-09-25",{"date":118,"type":37},"2025-10-01",{"date":120,"type":37},"2025-09-18",{"date":122,"type":21},"2027-06",{"name":124,"class":44},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":75},"100601971","phase-1-paclitaxel-cationic-liposome-hepatic-arterial-infusion-in-combination-with-systemic-therapy-as-first-line-treatment-in-colorectal-liver-metastases-100601971","NCT07117435","Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases","A Phase Ib\u002FIII Study to Evaluate the Safety and Efficacy of Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases","Inclusion Criteria:\n\n* 1\\. Age range: 18 - 75 years old (inclusive), gender not limited.\n* 2\\. For patients with colorectal liver metastases have been histologically or cytologically confirmed and who are assessed by multidisciplinary team (MDT) to be inoperable for radical surgical resection:\n\n  1. Have not received systemic treatment for the metastatic or recurrent disease;\n  2. For patients who have received neoadjuvant\u002Fadjuvant therapy before, the time interval between the last administration and disease progression must be ≥ 6 months;\n  3. Allow patients who have received local treatment and progressed.\n* 3\\. According to RECIST v1.1, at least one measurable lesion in the hepatic arterial infusion area (long diameter ≥ 1 cm and no previous local treatment).\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n* 5\\. Life expectancy of at least 3 months.\n* 6\\. Adequate organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factors within 14 days)\n* 7\\. Fertile patients (male and female) must agree to use reliable contraceptive methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the study and for at least 6 months after the last dose of study intervention. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.\n* 8\\. Fully understand the clinical study and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients known to have microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR), and have been evaluated by the investigators to be eligible for immune checkpoint inhibitor therapy.\n* 2\\. Patients known to have wild-type RAS and BRAF, and have been evaluated by the investigators to be eligible for anti-epidermal growth factor receptor (EGFR) drug therapy.\n* 3\\. Unresolved adverse reactions from previous anti-tumor treatments not yet recovered to CTCAE 5.0 grade ≤ 1 (except for alopecia or other toxicities deemed non-risky by the investigators).\n* 4\\. Central nervous system metastasis with clinical symptoms, or meningeal metastasis, or there are other evidences indicating that the patient's central nervous system metastasis or meningeal metastatic lesions have not been controlled, and the investigators judges that the patient is not suitable for enrollment.\n* 5\\. Patients with contraindications for transcatheter arterial infusion.\n* 6\\. Patients with active infections within 2 weeks prior to administration (NCI CTC AE v5.0 ≥ grade 2) (Defined as requiring intravenous administration of antibacterial, antifungal or antiviral drugs for treatment).\n* 7\\. Patients with grade 2 or above peripheral neuropathy (NCI CTC AE v5.0).\n* 8\\. Patients with a history of autoimmune diseases, immunodeficiency disorders, including HIV positive test results, or suffering from other acquired or congenital immune deficiencies, or those currently using immunosuppressive agents.\n* 9\\. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive with HBV DNA ≥ 2×103 IU\u002FmL (can use continuous antiviral treatment); or anti-hepatitis C virus antibody (HCV-Ab) positive with HCV RNA above the measurable limit; or active syphilis.\n* 10\\. Patients with known contraindications to capecitabine or oxaliplatin, paclitaxel or cationic liposome, or have severe allergic reactions; note: If the subject has contraindications to bevacizumab or has severe allergic reactions to any component of bevacizumab, it will not affect the enrollment but should not use bevacizumab in the study, and the specific reasons need to be recorded.\n* 11\\. Patients need to receive strong inducers and strong inhibitors of CYP2C8 and CYP3A4 within 2 weeks before the first study treatment or during the treatment.\n* 12\\. Patients had or have non-infectious pneumonia\u002Finterstitial lung disease that requires systemic glucocorticoid treatment.\n* 13\\. Severe cardiovascular disease history, including but not limited to:\n\n  * Long QT syndrome;\n  * High-degree atrioventricular block;\n  * Severe arrhythmia that is not well controlled by medication;\n  * Chronic heart failure history and NYHA cardiac function classification ≥ 3;\n  * Severe valvular regurgitation or stenosis that requires treatment;\n  * Acute coronary syndrome or severe myocardial disease within 6 months before screening;\n  * Uncontrolled hypertension;\n  * Echocardiography suggests LVEF \\\u003C 50%;\n* 14\\. Patients with a previous history of severe neurological or mental disorders (including epilepsy or dementia) lead to compliance issues.\n* 15\\. Patients with ultrasound-detected limb vascular thrombosis with potentially serious consequences during screening, or who with thromboembolic events within 3 months prior to enrollment.\n* 16\\. Patients with a history of severe bleeding, or who experienced major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, or purpura within the last 3 months.\n* 17\\. Any other reasons deemed by the investigators.",{"count":5,"type":21},[134],"PHASE1","This is a phase Ib\u002FIII, randomized, multicenter study evaluating the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.",[27,137],"First-line Treatment","2025-08-05",{"date":140,"type":37},"2025-08-12",{"date":142,"type":37},"2025-05-13",{"date":144,"type":21},"2026-06-01",{"name":146,"class":147},"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","INDUSTRY",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":154,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":75},"100575991","laparoscopic-associating-liver-partition-with-portal-vein-ligation-for-staged-hepatectomy-alpps-for-colorectal-liver-metastases-crlm-100575991","NCT06779474","Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)","Inclusion Criteria:\n\n1. Male or female subjects \\> 18 years \\\u003C 75 of age.\n2. ECOG performance status 0-1.\n3. Histologically confirmed colorectal adenocarcinoma.\n4. Imaging (CT or MRI) or pathological confirmation of liver metastasis.\n5. Child-Pugh grade A liver function.\n6. FLR\u002FsTLV (standardized total liver volume) \\\u003C 30% (patients without underlying liver diseases)or \\\u003C 40% (patients with liver diseases, such as hepatic steatosis, cirrhosis, or liver damage after chemotherapy).\n7. The indication of surgery is evaluated by a multidisciplinary team attended by hepatobiliary surgeons, oncologists, hepatologists and radiologists.\n\nExclusion Criteria:\n\n1. Patients with unresectable extrahepatic metastatic disease (except potentially resectable lung metastases) or primary tumor.\n2. Patients with severe concomitant diseases who are intolerance of major liver surgery by the judgment of the surgeon.\n3. Diagnosis of other malignant tumors within the past 5 years.\n4. Intention to become pregnant during the course of the study.\n5. Inability to comply with the study protocol.\n6. Previous enrollment in the current study.",{"count":155,"type":21},30,"Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a procedure used for patients with initially unresectable colorectal liver metastases (CRLM). However, the procedure has been reported to be associated with high morbidity and mortality. Laparoscopic ALPPS has recently been reported as a minimally invasive technique that reduces perioperative risks. This study aimed to assess the safety and feasibility of full laparoscopic ALPPS in patients with CRLM.",[27],[159,160,161],"Colorectal liver metastases","Associating liver partition and portal vein ligation for staged hepatectomy","Laparoscopic surgery","2025-04-13",{"date":164,"type":37},"2025-04-17",{"date":166,"type":21},"2025-05-01",{"date":168,"type":21},"2030-05-01",{"name":170,"class":44},"Yanhong Deng",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":5},"100459634","ablation-with-confirmation-of-colorectal-liver-metastases-acclaim-100459634","NCT05265169","Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)","Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure","ACCLAIM","Inclusion Criteria:\n\n1. Patient must be at least 18 years old.\n2. Patient has signed a written informed consent for the MWA and participation in the study.\n3. Patient with pathologically confirmed CRC with hepatic metastases confirmed on imaging (e.g., CT or MRI).\n4. Patient has up to 3 hepatic metastases, each up to 2.5 cm in largest diameter.\n5. Patient may have up to 5 lesions in the lung (none larger than ≥ 2.0 cm) and\u002For any lymph node ≤2.0 cm in the largest diameter\n6. Ability to safely create an ablation zone (AZ) that completely covers the tumor with minimal margin of 5.0 mm. Subcapsular (any tumor within 10 mm from the liver capsule) or perivascular (any tumor within 10 mm from a vessel larger than 3 mm) lesions may be included. For these tumors, the calculation of the margin will not apply to the area abutting the capsule or the vessel.\n7. The target tumor(s) is\u002Fare visible by US and\u002For CT in a location where MWA is technically achievable and safe based on the proximity to adjacent structures. Protective maneuvers such as hydrodissection for organ mobilization are allowed and will be recorded.\n8. ECOG performance status of 0-1.\n9. Platelet count \\>50,000\u002Fmm3 (correctable allowed) within 30 days prior to study treatment.\n\nExclusion Criteria:\n\n1. Patient is unable to lie flat or has respiratory distress at rest.\n2. Patient has uncontrolled and uncorrectable coagulopathy or bleeding disorders.\n3. Patient has a history of an allergic reaction to intravenous iodine that cannot be pre-medicated or prevents performance of a CT with IV contrast.\n4. Patient has evidence of active systemic infection.\n5. Patient has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up.\n6. Patient is currently participating in other experimental studies that could affect the primary endpoint.\n7. Patient unable to receive general anesthesia or adequate analgesia and sedation.\n8. Tumor location less than 25 mm from hilum (see diagrams with illustration of central ducts).\n9. Patient is currently pregnant or intends to become pregnant",{"count":180,"type":21},275,[24],"To demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of ≤ 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study.",[27],"2024-01-16",{"date":186,"type":37},"2024-01-17",{"date":188,"type":37},"2023-01-13",{"date":190,"type":21},"2027-12-10",{"name":192,"class":44},"Society of Interventional Oncology"]